FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

controls the trafficking and recycling of the pathogenic anti-GAD immunoglobulin G, making it a promising therapeutic target.In this case report, we describe the first efgartigimod treatment of three ...

Claim your 7-day free trial now. IgG4-RD is a chronic immune-mediated fibroinflammatory disorder that often manifests with tumor-like masses and/or painless enlargement of multiple organs.

It can block important immune functions that help fight cancer, making it harder for the body to attack tumors. The poster presentation titled “First in class Anti-CLEC-1A myeloid checkpoint ...

According to a study published in the journal ACS Pharmacology & Translational Science, the new drug has been shown to have neuroprotective and anti-inflammatory effects in two murine models of ...

They also meet our parameters for an anti-inflammatory diet, which means they can help reduce symptoms of chronic inflammation like joint pain, digestive issues and high blood pressure.

Encouraging efficacy data in a murine mesothelioma model with a selective ... with an anti-PD1 antibody in a murine model of mesothelioma. Immunohistochemistry of the tumors revealed a significant ...

Alumis’ lead clinical candidate, ESK-001, is a highly selective, next-generation oral TYK2 inhibitor that is designed to correct immune dysregulation across a spectrum of diseases driven by ...

To our knowledge, this is the first report of antitumor activity against mesothelioma using a selective A2B ... adenosine-mediated immune suppression, enhance anti-tumor responses, and broaden ...